IL135398A0 - Medicaments - Google Patents

Medicaments

Info

Publication number
IL135398A0
IL135398A0 IL13539898A IL13539898A IL135398A0 IL 135398 A0 IL135398 A0 IL 135398A0 IL 13539898 A IL13539898 A IL 13539898A IL 13539898 A IL13539898 A IL 13539898A IL 135398 A0 IL135398 A0 IL 135398A0
Authority
IL
Israel
Prior art keywords
medicaments
Prior art date
Application number
IL13539898A
Other languages
English (en)
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10820099&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL135398(A0) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of IL135398A0 publication Critical patent/IL135398A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
IL13539898A 1997-10-07 1998-10-05 Medicaments IL135398A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9721139.5A GB9721139D0 (en) 1997-10-07 1997-10-07 Medicaments
PCT/EP1998/006278 WO1999017755A2 (fr) 1997-10-07 1998-10-05 Medicaments

Publications (1)

Publication Number Publication Date
IL135398A0 true IL135398A0 (en) 2001-05-20

Family

ID=10820099

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13539898A IL135398A0 (en) 1997-10-07 1998-10-05 Medicaments

Country Status (36)

Country Link
US (3) US6284770B1 (fr)
EP (1) EP1021174A2 (fr)
JP (1) JP2001518495A (fr)
KR (1) KR20010015707A (fr)
CN (1) CN1281357A (fr)
AP (1) AP2000001785A0 (fr)
AR (1) AR017296A1 (fr)
AU (1) AU750818B2 (fr)
BR (1) BR9812886A (fr)
CA (1) CA2305751A1 (fr)
CO (1) CO5011096A1 (fr)
DZ (1) DZ2618A1 (fr)
EA (1) EA003184B1 (fr)
EE (1) EE200000214A (fr)
GB (1) GB9721139D0 (fr)
GT (1) GT199800157A (fr)
HN (1) HN1998000155A (fr)
HR (1) HRP20000198A2 (fr)
HU (1) HUP0003750A3 (fr)
ID (1) ID23874A (fr)
IL (1) IL135398A0 (fr)
IS (1) IS5425A (fr)
MA (1) MA26549A1 (fr)
NO (1) NO20001776L (fr)
NZ (1) NZ503698A (fr)
PA (1) PA8461101A1 (fr)
PE (1) PE120299A1 (fr)
PL (1) PL340337A1 (fr)
SK (1) SK4862000A3 (fr)
SV (1) SV1998000122A (fr)
TN (1) TNSN98179A1 (fr)
TR (1) TR200000913T2 (fr)
UY (1) UY25200A1 (fr)
WO (1) WO1999017755A2 (fr)
YU (1) YU20600A (fr)
ZA (1) ZA989061B (fr)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments
US7767203B2 (en) * 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
US6136807A (en) * 1998-11-10 2000-10-24 3M Innovative Properties Company Composition for the transdermal delivery of lerisetron
EP1090638A1 (fr) * 1999-10-08 2001-04-11 Sanofi-Synthelabo Utilisation de (R)-zacopride ou d'un de ses sels dans la fabrication d'un médicament pour le traitement de l'apnée du sommeil
TWI263496B (en) * 1999-12-10 2006-10-11 Novartis Ag Pharmaceutical combinations and their use in treating gastrointestinal disorders
DE10015783C2 (de) * 2000-03-30 2003-12-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System zur Abgabe von Lerisetron und seine Verwendung
JP2003533482A (ja) * 2000-05-18 2003-11-11 グラクソ グループ リミテッド 機能性消化不良の治療方法
AR028970A1 (es) * 2000-07-26 2003-05-28 Solvay Pharm Gmbh USO DE CILANSETRON O DE SUS SALES POR ADICIoN DE A CIDOS Y/O SOLVATOS FARMACOLoGICAMENTE COMPATIBLES PARA LA OBTENCIoN DE PREPARADOS FARMACEUTICOS PARA EL TRATAMIENTO Y/O LA PROFILAXIS DEL SíNDROME DEL INTESTINO IRRITABLE
US6566369B2 (en) 2000-07-26 2003-05-20 Solvay Pharmaceuticals Gmbh Medicament containing cilansetron for the treatment of non-obstipative male irritable bowel syndrome patients
JP2004508056A (ja) * 2000-09-06 2004-03-18 グラクソ　グループ　リミテッド ５−ヒドロキシトリプタミン受容体遺伝子多型、および治療に対する応答
GB0216027D0 (en) * 2002-07-10 2002-08-21 Arachnova Therapeutics Ltd New therapeutic use
US20040048874A1 (en) * 2001-05-22 2004-03-11 Bardsley Hazel Judith New therapeutic use of 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D]pyrimidine
EP2266558B1 (fr) * 2001-06-07 2017-04-19 Analgesic Neuropharmaceuticals, LLC Traitement de la douleur neuropathique avec l'antagoniste du récepteur du N-méthyl-D-aspartate dextrométhorphan
US7045549B2 (en) * 2001-11-08 2006-05-16 The Board Of Trustees Of The Leland Stanford Jr. University Treatment of symptoms associated with irritable bowel syndrome
JP2005523892A (ja) 2002-01-18 2005-08-11 アリックス セラピューティクス ５−ｈｔ３受容体アンタゴニストおよび使用法
DE60326585D1 (de) * 2002-07-10 2009-04-23 Dynogen Pharmaceuticals Inc 4-(2-fluorophenyl)-6-methyl-2(1-piperazinyl)thieno(2,3-d) pyrimidin bei der behandlung von funktionalen darmstörungen
DE10232750A1 (de) * 2002-07-18 2004-02-05 Basf Ag Verfahren zur Herstellung von macrocyclischen Ketonen durch Dieckmann-Kondensation in der Gasphase
AU2003252738A1 (en) * 2002-08-09 2004-02-25 Ajinomoto Co., Inc. Remedy for intestinal diseases and visceral pain
US20030187017A1 (en) * 2002-11-14 2003-10-02 Mangel Allen Wayne Method for treating functional dyspepsia
EP1567163B1 (fr) * 2003-01-13 2007-04-11 Dynogen Pharmaceuticals Inc. Methode pour traiter des nausees, des vomissements, des haut-le-coeur ou une association de ces symptomes
NZ541008A (en) * 2003-01-13 2007-09-28 Dynogen Pharmaceuticals Inc Method of treating functional bowel disorders
JO2735B1 (en) 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formations of balloonosterone
ZA200409537B (en) * 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
EP1594493A2 (fr) * 2003-12-16 2005-11-16 Teva Pharmaceutical Industries Ltd. Formes polymorphiques de la base du tegaserod et des sels de celui-ci
US7358270B2 (en) 2004-01-30 2008-04-15 Astellas Pharma Inc. Treating agent for irritable bowel syndrome
JP3763360B2 (ja) * 2004-01-30 2006-04-05 アステラス製薬株式会社 下痢型過敏性腸症候群治療剤
WO2005073220A1 (fr) * 2004-01-30 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Remede contre le syndrome du colon irritable avec diarrhee
NZ541656A (en) * 2004-01-30 2008-05-30 Astellas Pharma Inc The use of ramosetron hydrochloride for diarrhea-predominant irritable bowel syndrome
CA2555256A1 (fr) * 2004-02-03 2005-08-25 The Regents Of The University Of California Methodes de traitement du syndrome du colon irritable
JP4559749B2 (ja) * 2004-02-16 2010-10-13 あすか製薬株式会社 ピペラジニルピリジン誘導体
JP4912145B2 (ja) * 2004-02-26 2012-04-11 あすか製薬株式会社 ピリミジン誘導体
JP2006028028A (ja) * 2004-07-12 2006-02-02 Teikoku Medix Kk 経口医薬組成物
US20060293309A1 (en) * 2005-03-28 2006-12-28 Dynogen Pharmaceuticals, Inc. Method of treating disorders and conditions using peripherally-restricted antagonists and inhibitors
ES2359673T3 (es) * 2005-06-07 2011-05-25 Theravance, Inc. Compuestos de benzoimidazolona-carboxamida como agonista del receptor 5-ht4.
WO2007000046A1 (fr) * 2005-06-27 2007-01-04 Holburn Biomedical Corporation Methodes de diagnostic de maladie intestinale fonctionnelle
JP4632204B2 (ja) * 2005-09-21 2011-02-16 アステラス製薬株式会社 下痢型過敏性腸症候群治療剤
CN101384550B (zh) * 2006-02-20 2011-08-31 安斯泰来制药株式会社 酰胺衍生物或其盐
WO2009053750A2 (fr) 2007-10-24 2009-04-30 Generics [Uk] Limited Nouvelles formes cristallines et amorphes
WO2009053732A1 (fr) 2007-10-24 2009-04-30 Generics [Uk] Limited Nouveau sel
WO2009053733A2 (fr) 2007-10-24 2009-04-30 Generics [Uk] Limited Nouvelles formes cristallines
WO2009053754A2 (fr) 2007-10-24 2009-04-30 Generics [Uk] Limited Nouvelles formes cristallines
US8734867B2 (en) * 2007-12-28 2014-05-27 Liveleaf, Inc. Antibacterial having an extract of pomegranate combined with hydrogen peroxide
HUE049150T2 (hu) 2009-03-04 2021-12-28 Liveleaf Inc Eljárás és anyag biológiai molekulák helyhez aktivált komplexképzésére
JP5836264B2 (ja) 2009-04-29 2015-12-24 ガネーデン バイオテック インコーポレイテッド 不活性化細菌細胞製剤
JP5741433B2 (ja) * 2009-06-30 2015-07-01 アステラス製薬株式会社 緩解期の炎症性腸疾患患者における排便異常治療剤
JP5938886B2 (ja) * 2010-12-14 2016-06-22 アステラス製薬株式会社 活動期の炎症性腸疾患患者における排便異常治療剤
US8722040B2 (en) 2011-06-24 2014-05-13 Liveleaf, Inc. Site-activated binding systems that selectively increase the bioactivity of phenolic compounds at target sites
US20120329736A1 (en) * 2011-06-24 2012-12-27 Huang Alexander L Treatment for gastrointestinal disorders using a selective, site-activated binding system
US9192635B2 (en) 2011-06-24 2015-11-24 Liveleaf, Inc. Method of treating damaged mucosal or gastrointestinal tissue by administering a composition comprising a mixture of pomegranate and green tea extracts and releasably bound hydrogen peroxide
DK2744497T3 (en) * 2011-10-18 2016-08-01 Helsinn Healthcare Sa THERAPEUTIC COMBINATION OF netupitant AND palonosetron
KR20200065113A (ko) 2012-09-05 2020-06-08 체이스 파마슈티칼스 코포레이션 항콜린 신경보호 조성물 및 그 방법
US8716351B1 (en) 2012-12-23 2014-05-06 Liveleaf, Inc. Methods of treating gastrointestinal spasms

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0254584B1 (fr) * 1986-07-25 1992-10-07 Beecham Group Plc Composés azabicycliques, procédé pour leur préparation et leur utilisation pharmaceutique
GB8806990D0 (en) 1988-03-23 1988-04-27 Beecham Group Plc Novel compounds
GB8701022D0 (en) * 1987-01-19 1987-02-18 Beecham Group Plc Treatment
ES2060655T3 (es) 1987-09-03 1994-12-01 Glaxo Group Ltd Derivados de lactamas.
EP0315390B1 (fr) * 1987-11-04 1994-07-20 Beecham Group Plc Composés nouveaux de 4-oxobenzotriazine et 4-oxoquinazoline
US5116984A (en) * 1988-04-07 1992-05-26 Glaxo Group Limited Imidazole derivatives
GB8814277D0 (en) 1988-06-16 1988-07-20 Glaxo Group Ltd Chemical compounds
NZ230068A (en) * 1988-07-29 1991-07-26 Dainippon Pharmaceutical Co Indazole-3-carboxylic acid esters and amides of diaza compounds having 6,7, or 8 ring members: preparatory processes and pharmaceutical compositions
GB8820650D0 (en) 1988-09-01 1988-10-05 Glaxo Group Ltd Medicaments
GB8823980D0 (en) * 1988-10-13 1988-11-23 Glaxo Group Ltd Chemical compounds
GB8829079D0 (en) * 1988-12-13 1989-01-25 Beecham Group Plc Novel compounds
GB8904551D0 (en) 1989-02-28 1989-04-12 Glaxo Group Ltd Chemical compounds
EP0387431A1 (fr) 1989-03-14 1990-09-19 Beecham Group Plc Dérivés d'imidazole, procédés de leur préparation et leur application comme produits pharmaceutiques
GB9020927D0 (en) 1990-09-26 1990-11-07 Beecham Group Plc Pharmaceuticals
GB9027098D0 (en) * 1990-12-13 1991-02-06 Beecham Group Plc Pharmaceuticals
GB9027487D0 (en) 1990-12-19 1991-02-06 Beecham Group Plc Pharmaceuticals
WO1992012149A1 (fr) * 1991-01-09 1992-07-23 Smithkline Beecham Plc Derives azabicydiques et azatricydiques, leurs procedes et intermediaires de preparation et compositions pharmaceutiques les contenant
GB9214184D0 (en) * 1992-07-03 1992-08-12 Smithkline Beecham Plc Pharmaceuticals
GB9721139D0 (en) * 1997-10-07 1997-12-03 Glaxo Group Ltd Medicaments

Also Published As

Publication number Publication date
PL340337A1 (en) 2001-01-29
HRP20000198A2 (en) 2001-04-30
AP2000001785A0 (en) 2000-06-30
KR20010015707A (ko) 2001-02-26
PA8461101A1 (es) 2000-05-24
JP2001518495A (ja) 2001-10-16
NZ503698A (en) 2002-10-25
EE200000214A (et) 2001-06-15
US6593336B2 (en) 2003-07-15
WO1999017755A2 (fr) 1999-04-15
SV1998000122A (es) 1999-07-05
US20010044450A1 (en) 2001-11-22
EP1021174A2 (fr) 2000-07-26
CN1281357A (zh) 2001-01-24
TR200000913T2 (tr) 2001-01-22
GB9721139D0 (en) 1997-12-03
UY25200A1 (es) 2001-01-31
ZA989061B (en) 2001-07-05
AR017296A1 (es) 2001-09-05
HUP0003750A3 (en) 2003-02-28
HN1998000155A (es) 1999-05-24
CO5011096A1 (es) 2001-02-28
ID23874A (id) 2000-05-25
MA26549A1 (fr) 2004-12-20
PE120299A1 (es) 1999-12-15
US6284770B1 (en) 2001-09-04
BR9812886A (pt) 2000-08-08
AU9629398A (en) 1999-04-27
WO1999017755A3 (fr) 1999-09-23
GT199800157A (es) 2000-03-30
IS5425A (is) 2000-03-31
NO20001776L (no) 2000-06-06
DZ2618A1 (fr) 2003-03-01
HUP0003750A2 (hu) 2001-10-28
EA003184B1 (ru) 2003-02-27
AU750818B2 (en) 2002-07-25
TNSN98179A1 (fr) 2005-03-15
CA2305751A1 (fr) 1999-04-15
US20030036549A1 (en) 2003-02-20
NO20001776D0 (no) 2000-04-06
US6429209B2 (en) 2002-08-06
SK4862000A3 (en) 2001-01-18
EA200000299A1 (ru) 2000-12-25
YU20600A (sh) 2003-10-31

Similar Documents

Publication Publication Date Title
GB9721139D0 (en) Medicaments
GB9606805D0 (en) Medicaments
GB9702021D0 (en) Medicaments
GB9718791D0 (en) Medicaments
GB9611947D0 (en) Medicaments
GB9605293D0 (en) Medicaments
GB9618974D0 (en) Medicaments
GB2320900B (en) Inhalers
GB9828620D0 (en) Medicaments
GB9611167D0 (en) Medicaments
GB9613096D0 (en) Medicaments
GB9700908D0 (en) Medicaments
GB9723506D0 (en) Medicaments
GB9723061D0 (en) Medicaments
GB9702132D0 (en) Medicaments
GB9703045D0 (en) Medicaments
GB9700323D0 (en) Combined medicaments
GB2329335B (en) Medicament
GB0002424D0 (en) Medicament
GB9702946D0 (en) Medicament
GB9726234D0 (en) Medicament
GB9623160D0 (en) Medicaments
GB9600641D0 (en) Medicaments
GB9605291D0 (en) Medicaments
GB9605292D0 (en) Medicaments